A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
Launched by BISPEBJERG HOSPITAL · Jun 11, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients registered in the Danish Heart Failure Registry who has a baseline left ventricular ejection fraction \<40% and who has filled in a prescription for an aldosterone antagonist
- Exclusion Criteria:
- • patients who had filled in a prescription for an aldosterone antagonist prior ro registration in the Danish Heart Failure Registry
About Bispebjerg Hospital
Bispebjerg Hospital is a leading healthcare institution located in Copenhagen, Denmark, renowned for its commitment to innovative medical research and clinical excellence. As a key sponsor of clinical trials, the hospital focuses on advancing healthcare by exploring novel therapies and treatment protocols across various medical disciplines. With a multidisciplinary team of experienced researchers and clinicians, Bispebjerg Hospital aims to enhance patient outcomes through rigorous scientific inquiry and evidence-based practices, while fostering collaboration with academic institutions and industry partners to drive progress in the medical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Jens Jakob Thune, MD, PhD
Study Chair
Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials